Rhythm Pharmaceuticals Inc
Gesloten
SectorGezondheidszorg
104.62 2.4
Overzicht
Wijziging aandelenprijs
24u
Min
103.67
Max
106.1
Inkomsten | -49M -105M |
|---|---|
Verkoop | 11M 71M |
EPS | -0.73 |
Winstmarge | -147.27 |
Werknemers | 414 |
EBITDA | 6.2M -44M |
Volgende Winsten | 3 nov 2026 |
|---|
Marktkapitalisatie | 24M 7.1B |
|---|---|
Vorige openingsprijs | 102.22 |
Vorige sluitingsprijs | 104.62 |
Nieuwssentiment
By Acuity
64%
36%
285 / 339 Rangschikking in Healthcare
Rhythm Pharmaceuticals Inc Grafiek
Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.
Gerelateerd nieuws
Peer Vergelijking
Prijswijziging
Rhythm Pharmaceuticals Inc Prognose
Sentiment
By Acuity
285 / 339 Rangschikking in Gezondheidszorg
Nieuwssentiment
Bullish Bewijs
Volatiliteit
Onder gemiddelde
Nieuws Volume (RCV)
Onder gemiddelde
Financieel
Verkoop- en administratiekosten
Bedrijfskosten
Winst voor belastingen
Verkoop
Kosten van verkopen
Brutowinst op verkopen
Rente-uitgaven op schulden
EBITDA
Operationele winst
$
Over Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.